Related references
Note: Only part of the references are listed.Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenstrom's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE™ Trial
Judith Trotman et al.
BLOOD (2020)
Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE™ Study
Christian Buske et al.
BLOOD (2020)
Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenstrom macroglobulinaemia
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies
Avirup Guha et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
CXCL13 levels are elevated in patients with Waldenstrom macroglobulinemia, and are predictive of major response to ibrutinib
Josephine M. Vos et al.
HAEMATOLOGICA (2017)
Ibrutinib for patients with rituximab-refractory Waldenstrm's macro globulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
CXCL13 levels are elevated in patients with Waldenstrom macroglobulinemia, and are predictive of major response to ibrutinib
Josephine M. Vos et al.
HAEMATOLOGICA (2017)
Ventricular arrhythmias and sudden death in patients taking ibrutinib
Benjamin L. Lampson et al.
BLOOD (2017)
Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia
Lian Xu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88L265P-directed survival signalling in Waldenstrom macroglobulinaemia cells
Yang Cao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R. Hunter et al.
BLOOD (2014)
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
Guang Yang et al.
BLOOD (2013)
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
Meletios A. Dimopoulos et al.
BLOOD (2013)
Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop
Roger G. Owen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Primary Therapy of Waldenstrom Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RG Owen et al.
SEMINARS IN ONCOLOGY (2003)
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RA Kyle et al.
SEMINARS IN ONCOLOGY (2003)
Share Paper
